- |||||||||| Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Trial completion date, Trial primary completion date: Study of Nasal Insulin to Fight Forgetfulness - Device Study (clinicaltrials.gov) - Dec 15, 2023
P2, N=30, Active, not recruiting,
Additionally, KBP-336 may prevent hypoglycaemia and improve insulin resistance, which could be a significant advantage for individuals with T1D seeking therapeutic benefits. Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Aug 2025
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk, Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Trial completion date, Trial primary completion date: LEV PS: Dose Response Study of Transdermal Human Insulin in Patients (clinicaltrials.gov) - Sep 6, 2023
P2/3, N=30, Not yet recruiting,
Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Aug 2025 Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk, Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Trial primary completion date: LEV PS: Dose Response Study of Transdermal Human Insulin in Patients (clinicaltrials.gov) - Jun 15, 2023
P2/3, N=30, Not yet recruiting,
Plasma insulin was assayed after a single dose (1.5 U/kg) of diluted insulin human (Humulin Trial primary completion date: Sep 2023 --> Dec 2023
- |||||||||| Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Enrollment open: Safety of Topical Insulin Drops for Open-angle Glaucoma (clinicaltrials.gov) - Apr 5, 2023
P1, N=18, Recruiting,
Recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Trial withdrawal: Neural Mechanism of Aldosterone-induced Insulin Resistance (clinicaltrials.gov) - Mar 15, 2023
P4, N=0, Withdrawn,
Not yet recruiting --> Recruiting Recruiting --> Withdrawn
- |||||||||| ultra-rapid-acting concentrated insulin aspart (AT278) / Arecor
New P1 trial: AT278, NovoRapid (clinicaltrials.gov) - Mar 3, 2023
P1, N=32, Recruiting,
- |||||||||| Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Enrollment change, Trial completion date: Study of Nasal Insulin to Fight Forgetfulness - Device Study (clinicaltrials.gov) - Jan 31, 2023
P2, N=30, Active, not recruiting,
Recruiting --> Withdrawn N=21 --> 30 | Trial completion date: Aug 2025 --> Aug 2024
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk, Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Trial primary completion date: LEV PS: Dose Response Study of Transdermal Human Insulin in Patients (clinicaltrials.gov) - Jan 31, 2023
P2/3, N=30, Not yet recruiting,
N=21 --> 30 | Trial completion date: Aug 2025 --> Aug 2024 Trial primary completion date: Mar 2023 --> Sep 2023
- |||||||||| Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Trial completion date, Trial primary completion date: Safety of Topical Insulin Drops for Open-angle Glaucoma (clinicaltrials.gov) - Nov 30, 2022
P1, N=15, Not yet recruiting,
PK and PD equivalence was demonstrated between Biocon's Insulin-N and Humulin-N in healthy subjects and both treatments were well tolerated and considered safe. Trial completion date: Nov 2022 --> Nov 2024 | Trial primary completion date: Aug 2022 --> Feb 2024
- |||||||||| Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Trial completion date, Trial primary completion date: SNIFF Multi-Device Study 2 (clinicaltrials.gov) - Nov 1, 2022
P2, N=30, Active, not recruiting,
Trial completion date: Nov 2022 --> Nov 2024 | Trial primary completion date: Aug 2022 --> Feb 2024 Trial completion date: Oct 2023 --> Oct 2025 | Trial primary completion date: Oct 2022 --> Oct 2024
- |||||||||| Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Trial completion, Trial completion date, Trial primary completion date: Dose-Finding Study of Intranasal Insulin in Healthy Participants Insulin in Healthy Participants (clinicaltrials.gov) - Oct 14, 2022
P1, N=24, Completed,
Trial completion date: Oct 2023 --> Oct 2025 | Trial primary completion date: Oct 2022 --> Oct 2024 Recruiting --> Completed | Trial completion date: Oct 2023 --> Apr 2022 | Trial primary completion date: Oct 2023 --> Apr 2022
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk, Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Trial completion date, Trial initiation date, Trial primary completion date: LEV PS: Dose Response Study of Transdermal Human Insulin in Patients (clinicaltrials.gov) - Oct 13, 2022
P2/3, N=30, Not yet recruiting,
Recruiting --> Completed | Trial completion date: Oct 2023 --> Apr 2022 | Trial primary completion date: Oct 2023 --> Apr 2022 Trial completion date: Dec 2022 --> Dec 2023 | Initiation date: Oct 2022 --> Jan 2023 | Trial primary completion date: Dec 2022 --> Mar 2023
- |||||||||| Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Journal: Glycemic Outcomes of Hospitalized Patients on Ambulatory Humulin-R U-500 Insulin. (Pubmed Central) - Oct 4, 2022
Inpatient insulin doses of 40% of home TDD or ≤ 0.6 unit/kg were not associated with increased hypoglycemia risk. Further prospective studies are needed to determine effective doses in these high-risk patients.
- |||||||||| Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Review, Journal: Current trends in biopharmaceuticals production in Escherichia coli. (Pubmed Central) - Aug 11, 2022
In the past 10 years, with increased growth of antibody-based therapies, mammalian hosts particularly CHO cells have dominated. However, with new antibody like scaffolds and mimetics emerging as future proteins of interest, E. coli has again the opportunity to be the selected as the production system of choice.
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk, Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Trial initiation date, Trial primary completion date: LEV PS: Dose Response Study of Transdermal Human Insulin in Patients (clinicaltrials.gov) - Jul 14, 2022
P2/3, N=30, Not yet recruiting,
However, with new antibody like scaffolds and mimetics emerging as future proteins of interest, E. coli has again the opportunity to be the selected as the production system of choice. Initiation date: Jun 2022 --> Oct 2022 | Trial primary completion date: Aug 2022 --> Dec 2022
- |||||||||| Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Trial completion date, Trial initiation date, Trial primary completion date: SNIFF - 3-Week Aptar CPS Device (clinicaltrials.gov) - Jun 1, 2022
P2, N=40, Not yet recruiting,
Wider entry to the pharmaceutical market of affordable, biosimilar regular insulins may substantially improve access to insulin for many socioeconomically disadvantaged patients with diabetes. Trial completion date: May 2026 --> May 2031 | Initiation date: May 2022 --> May 2025 | Trial primary completion date: May 2025 --> May 2029
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk, Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Trial initiation date: LEV PS: Dose Response Study of Transdermal Human Insulin in Patients (clinicaltrials.gov) - Apr 4, 2022
P2/3, N=30, Not yet recruiting,
The elevated RBC sO in ZDSD rats may indicate a dysregulation of capillary blood flow in the ZDSD model. Initiation date: Mar 2022 --> Jun 2022
- |||||||||| Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Trial completion: Glucose Control in Severely Burned Patients (clinicaltrials.gov) - Mar 28, 2022
P=N/A, N=45, Completed,
Treatment with Biocon's Insulin-R and Humulin® R was well tolerated. Recruiting --> Completed
- |||||||||| Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Trial completion date, Trial primary completion date: Study of Nasal Insulin to Fight Forgetfulness - Device Study (clinicaltrials.gov) - Feb 11, 2022
P2, N=21, Active, not recruiting,
Imposing dTDDs > 200 units before switching to U-500R criterion could hurt the opportunities for patients who need a simplified regimen for better outcomes. Trial completion date: Aug 2022 --> Aug 2025 | Trial primary completion date: Aug 2022 --> Aug 2024
- |||||||||| Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Journal: Insulin Regulation of Escherichia coli Abiotic Biofilm Formation: Effect of Nutrients and Growth Conditions. (Pubmed Central) - Nov 29, 2021
Micropipette tips were incubated with E. coli ATCC 25922™ in a Mueller Hinton broth (MH), or a yeast nitrogen base with 1% peptone (YNBP), which was supplemented with glucose, lactose, galactose and/or insulin (Humulin-R)...E. coli biofilm formation is influenced by aeration, temperature, and insulin concentration in combination with the available sugars.
- |||||||||| Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Enrollment open: SNIFF - Combo INI+EMPA Trial (clinicaltrials.gov) - Nov 11, 2021
P2, N=60, Recruiting,
coli biofilm formation is influenced by aeration, temperature, and insulin concentration in combination with the available sugars. Not yet recruiting --> Recruiting
- |||||||||| Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Trial completion date, Trial initiation date, Trial primary completion date: SNIFF - 3-Week Aptar CPS Device (clinicaltrials.gov) - Nov 8, 2021
P2, N=40, Not yet recruiting,
Not yet recruiting --> Recruiting Trial completion date: Oct 2025 --> May 2026 | Initiation date: Oct 2021 --> May 2022 | Trial primary completion date: Oct 2024 --> May 2025
- |||||||||| Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Enrollment closed: SNIFF Multi-Device Study 2 (clinicaltrials.gov) - Nov 4, 2021
P2, N=30, Active, not recruiting,
Trial completion date: Oct 2025 --> May 2026 | Initiation date: Oct 2021 --> May 2022 | Trial primary completion date: Oct 2024 --> May 2025 Recruiting --> Active, not recruiting
- |||||||||| Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Trial completion date, Trial primary completion date, Surgery: Effect of Intranasal Insulin on POCD and POD (clinicaltrials.gov) - Oct 21, 2021
P=N/A, N=494, Not yet recruiting,
Intranasal insulin treatment for 12 months reduced white matter hyperintensity volume progression and supports insulin's potential as a therapeutic option for Alzheimer's disease. Trial completion date: Jun 2023 --> Nov 2024 | Trial primary completion date: Jun 2023 --> Nov 2023
- |||||||||| Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
New P2 trial: SNIFF - Combo INI+EMPA Trial (clinicaltrials.gov) - Oct 17, 2021
P2, N=60, Not yet recruiting,
- |||||||||| Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Enrollment open: Brain Insulin Resistance in Mood Disorders (clinicaltrials.gov) - Oct 14, 2021
P1/2, N=150, Recruiting,
Trial completion date: Jun 2023 --> Nov 2024 | Trial primary completion date: Jun 2023 --> Nov 2023 Not yet recruiting --> Recruiting
- |||||||||| Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Clinical, Journal: Engineering Insulin Cold Chain Resilience to Improve Global Access. (Pubmed Central) - Sep 29, 2021
Further, when these copolymers are added to Humulin R (Eli Lilly) in original commercial packaging, they prevent insulin aggregation for up to 4 days at 50 °C compared to less than 1 day for Humulin R alone. These copolymers demonstrate promise as simple formulation additives to increase the cold chain resilience of commercial insulin formulations, thereby expanding global access to these critical drugs for treatment of diabetes.
- |||||||||| Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Phase classification, Enrollment change, Trial completion date, Trial primary completion date: Brain Insulin Resistance in Mood Disorders (clinicaltrials.gov) - Sep 23, 2021
P1/2, N=150, Not yet recruiting,
These copolymers demonstrate promise as simple formulation additives to increase the cold chain resilience of commercial insulin formulations, thereby expanding global access to these critical drugs for treatment of diabetes. Phase classification: P1 --> P1/2 | N=25 --> 150 | Trial completion date: Sep 2020 --> Sep 2024 | Trial primary completion date: May 2020 --> Sep 2024
- |||||||||| Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Trial completion date, Trial suspension, Trial primary completion date: Safety of Topical Insulin Drops for Open-angle Glaucoma (clinicaltrials.gov) - Aug 20, 2021
P1, N=15, Suspended,
Phase classification: P1 --> P1/2 | N=25 --> 150 | Trial completion date: Sep 2020 --> Sep 2024 | Trial primary completion date: May 2020 --> Sep 2024 Trial completion date: Nov 2021 --> Nov 2022 | Not yet recruiting --> Suspended | Trial primary completion date: Nov 2020 --> Aug 2022
|
